Cardiovascular Disease Research

At APDP Associacao Protectora Dos Diabeticos De Portugal in Lisbon, clinical trials in cardiovascular diseases focus on major conditions such as atherosclerotic cardiovascular disease, hypertension, and prevention of serious heart and brain events. The research is aimed at evaluating new treatments that may lower the risk of heart attack, stroke, and related complications in people at elevated risk.

  • Studies in adults at high risk of cardiovascular events without prior heart attack or stroke
  • Research on treatments for atherosclerotic cardiovascular disease and cardiovascular disease outcomes
  • Trials assessing prevention of major events such as heart attack, stroke, and cardiovascular death

This work is helping to evaluate whether newer therapies can improve long-term cardiovascular protection alongside standard care.

Digestive System and Liver Disease Research

The site also studies digestive system diseases, with a strong focus on metabolic dysfunction-associated steatotic liver disease and non-alcoholic steatohepatitis (NASH). These trials are designed to test whether new treatments can improve liver health, reduce disease progression, and lower the chance of liver-related complications.

  • Trials in Metabolic Dysfunction-Associated Steatotic Liver Disease and non-alcoholic steatohepatitis
  • Research evaluating improvement in liver health and disease outcomes
  • Studies aimed at reducing the risk of liver-related clinical events

This research reflects an effort to find better options for people living with chronic liver disease linked to metabolic health.

Nutritional and Metabolic Disease Research

A major part of the clinical trial portfolio at APDP Associacao Protectora Dos Diabeticos De Portugal centers on nutritional and metabolic diseases, including type 2 diabetes, obesity, chronic kidney disease, and related complications. The studies are exploring new therapies to improve weight control, kidney health, blood sugar management, and eye outcomes in people with diabetes.

  • Trials in type 2 diabetes and diabetic eye disease
  • Research on obesity and long-term weight reduction
  • Studies in chronic kidney disease and urinary albumin reduction

The overall goal is to assess whether emerging treatments can better support metabolic control and reduce the burden of diabetes-related complications.